Aricept Warnings and Precautions
Links shared publicly online about this topic
ARICEPT (Donepezil) drug information from MPR
empr.com — “ARICEPT (Donepezil) drug information for Alzheimer's dementia from MPR including side effects, drug interactions, dosing, contraindications and warnings/precautions.” View full resource at empr.com
Most Recently Shared on September 10, 2010 at 4:23 am By:
MPR News: ARICEPT: 23mg tablet available. Adults: dosing updated. Adverse reactions: weight loss (esp. with 23mg/d... http://bit.ly/a3roNQ
FDA Approved Higher Aricept Dose Despite Warning // Pharmalot
pharmalot.com — “FDA Approved Higher Aricept Dose Despite Warning // Pharmalot” View full resource at pharmalot.com
Most Recently Shared on March 23, 2012 at 1:01 pm By:
FDA Approved Higher Aricept Dose Despite Warning http://t.co/iCjj0VNL
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 3:32 pm By:
George Huba, Ph.D. Psychologist, PhD, and Doctor
NYT: Drug Dosage Was Approved Despite Warning - Aricept 23 was developed by the Japanese pharmaceutical company Eisa... http://t.co/KAZJYoT9
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 5:44 am By:
Drug Dosage Was Approved Despite Warning: The Alzheimer’s drug Aricept 23 was set to lose its patent, but its ma... http://t.co/jE15Ig2q
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 5:25 am By:
HealthTrendster Health Executive
Drug Dosage Was Approved Despite Warning - Aricept 23 was developed by the Japanese pharmaceutical company Eisai and... http://t.co/59MH8fp0
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 1:05 pm By:
Susan Krauss Whitbourne Doctor, Psychologist, and PhD
Chilling tale about Aricept's approval for stronger dose despite high risks and lack of effectiveness. #pharma #psych http://t.co/wUEvIdMi
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 11:05 am By:
Drug Dosage Was Approved Despite Warning http://t.co/Mk0uqRGH
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 2:47 am By:
Healthcare Channel Health Site
NYT Drug Dosage Was Approved Despite Warning http://t.co/K49bHdyF
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 1:57 pm By:
NYT: Drug Dosage Was Approved Despite Warning http://t.co/inId49mN
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 1:57 pm By:
NYT: Drug Dosage Was Approved Despite Warning http://t.co/inId49mN
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 11:49 am By:
Kent Bottles, MD Doctor, Pathologist, and Physician
Drug Dosage Was Approved Despite Warning: http://t.co/3Yuby2Wo
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 24, 2012 at 3:58 am By:
Drug Dosage Was Approved Despite Warning: http://t.co/gLW3RU6E
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 11:06 pm By:
Amy Berman Health Organization
Deeply disturbing piece from NYTimes: Drug Dosage Was Approved Despite Warning http://t.co/msEYrQdM
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 24, 2012 at 8:30 pm By:
Should this #Alzheimer drug's patent have been extended despite warning about troubling side effects? http://t.co/uGGdCFg2
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 23, 2012 at 1:01 pm By:
Dr. Steven Z. Kussin Doctor, Internist, Gastroenterologist, and Physician
Two articles on your friendly BigPhama companies and Device companies. You are spending too much time worrying... http://t.co/AqRbDd1B
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
pharmalot
The latest news and views about the pharmaceutical industry, with Ed Silverman of Pharmalot.com.
-
George Huba, Ph.D.
evaluator of health/social service agencies; psychologist; researcher on drug abuse, HIV, mental health, HC reform, geriatrics; CEO of The Measurement Group
Advertisement
